NLS PHARMACEUTICS LTD's ticker is NLSP and the CUSIP is H57830103. A total of 5 filers reported holding NLS PHARMACEUTICS LTD in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15 | -75.0% | 21,100 | -61.4% | 0.00% | – |
| Q2 2023 | $60 | +22.4% | 54,700 | +70.4% | 0.00% | – |
| Q1 2023 | $49 | +88.5% | 32,100 | +58.9% | 0.00% | – |
| Q4 2022 | $26 | -99.8% | 20,200 | -21.7% | 0.00% | – |
| Q3 2022 | $16,000 | +33.3% | 25,800 | +29.0% | 0.00% | – |
| Q2 2022 | $12,000 | -61.3% | 20,000 | -7.8% | 0.00% | – |
| Q1 2022 | $31,000 | +158.3% | 21,700 | +100.9% | 0.00% | – |
| Q4 2021 | $12,000 | -90.9% | 10,800 | -74.3% | 0.00% | – |
| Q2 2021 | $132,000 | – | 41,997 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Renaissance Technologies | 21,700 | $31,000 | 0.00% |
| UBS Group AG | 10,582 | $15,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 14,362 | $20,000 | 0.00% |
| Citadel Advisors | 21,632 | $31,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 3,665 | $5,000 | 0.00% |